Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis

CONCLUSION: At the current price, MIRV for PROC with high-FRα expression is not the cost-effective strategy in the US. However, its treatment has higher health benefits in bevacizumab-naïve patients, which is likely to be an alternative.PMID:38576343 | DOI:10.3802/jgo.2024.35.e71
Source: Journal of Gynecologic Oncology - Category: OBGYN Authors: Source Type: research